World Workshop on Oral Medicine VI: Clinical implications of medication-induced salivary gland dysfunction

Ardita Aliko, Andy Wolff, Colin Dawes, Doron Aframian, Gordon Proctor, Jörgen Ekström, Nagamani Narayana, Alessandro Villa, Ying Wai Sia, Revan Kumar Joshi, Richard McGowan, Siri Beier Jensen, A. Ross Kerr, Anne Marie Lynge Pedersen, Arjan Vissink

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objective This study aimed to systematically review the available literature on the clinical implications of medication-induced salivary gland dysfunction (MISGD). Study Design The systematic review was performed using PubMed, Embase, and Web of Science (through June 2013). Studies were assessed for degree of relevance and strength of evidence, based on whether clinical implications of MISGD were the primary study outcomes, as well as on the appropriateness of study design and sample size. Results For most purported xerogenic medications, xerostomia was the most frequent adverse effect. In the majority of the 129 reviewed papers, it was not documented whether xerostomia was accompanied by decreased salivary flow. Incidence and prevalence of medication-induced xerostomia varied widely and was often associated with number and dose of medications. Xerostomia was most frequently reported to be mild-to-moderate in severity. Its onset occurred usually in the first weeks of treatment. There was selected evidence that medication-induced xerostomia occurs more frequently in women and older adults and that MISGD may be associated with other clinical implications, such as caries or oral mucosal alterations. Conclusions The systematic review showed that MISGD constitutes a significant burden in many patients and may be associated with important negative implications for oral health.

Original languageEnglish (US)
Pages (from-to)185-206
Number of pages22
JournalOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Volume120
Issue number2
DOIs
StatePublished - Jan 1 2015

Fingerprint

Oral Medicine
Xerostomia
Salivary Glands
Education
Oral Health
PubMed
Sample Size
Outcome Assessment (Health Care)
Incidence

ASJC Scopus subject areas

  • Surgery
  • Oral Surgery
  • Pathology and Forensic Medicine
  • Dentistry (miscellaneous)
  • Radiology Nuclear Medicine and imaging

Cite this

World Workshop on Oral Medicine VI : Clinical implications of medication-induced salivary gland dysfunction. / Aliko, Ardita; Wolff, Andy; Dawes, Colin; Aframian, Doron; Proctor, Gordon; Ekström, Jörgen; Narayana, Nagamani; Villa, Alessandro; Sia, Ying Wai; Joshi, Revan Kumar; McGowan, Richard; Beier Jensen, Siri; Kerr, A. Ross; Lynge Pedersen, Anne Marie; Vissink, Arjan.

In: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, Vol. 120, No. 2, 01.01.2015, p. 185-206.

Research output: Contribution to journalArticle

Aliko, A, Wolff, A, Dawes, C, Aframian, D, Proctor, G, Ekström, J, Narayana, N, Villa, A, Sia, YW, Joshi, RK, McGowan, R, Beier Jensen, S, Kerr, AR, Lynge Pedersen, AM & Vissink, A 2015, 'World Workshop on Oral Medicine VI: Clinical implications of medication-induced salivary gland dysfunction', Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, vol. 120, no. 2, pp. 185-206. https://doi.org/10.1016/j.oooo.2014.10.027
Aliko, Ardita ; Wolff, Andy ; Dawes, Colin ; Aframian, Doron ; Proctor, Gordon ; Ekström, Jörgen ; Narayana, Nagamani ; Villa, Alessandro ; Sia, Ying Wai ; Joshi, Revan Kumar ; McGowan, Richard ; Beier Jensen, Siri ; Kerr, A. Ross ; Lynge Pedersen, Anne Marie ; Vissink, Arjan. / World Workshop on Oral Medicine VI : Clinical implications of medication-induced salivary gland dysfunction. In: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2015 ; Vol. 120, No. 2. pp. 185-206.
@article{bcafb98edebc4b8489483604586ec9fd,
title = "World Workshop on Oral Medicine VI: Clinical implications of medication-induced salivary gland dysfunction",
abstract = "Objective This study aimed to systematically review the available literature on the clinical implications of medication-induced salivary gland dysfunction (MISGD). Study Design The systematic review was performed using PubMed, Embase, and Web of Science (through June 2013). Studies were assessed for degree of relevance and strength of evidence, based on whether clinical implications of MISGD were the primary study outcomes, as well as on the appropriateness of study design and sample size. Results For most purported xerogenic medications, xerostomia was the most frequent adverse effect. In the majority of the 129 reviewed papers, it was not documented whether xerostomia was accompanied by decreased salivary flow. Incidence and prevalence of medication-induced xerostomia varied widely and was often associated with number and dose of medications. Xerostomia was most frequently reported to be mild-to-moderate in severity. Its onset occurred usually in the first weeks of treatment. There was selected evidence that medication-induced xerostomia occurs more frequently in women and older adults and that MISGD may be associated with other clinical implications, such as caries or oral mucosal alterations. Conclusions The systematic review showed that MISGD constitutes a significant burden in many patients and may be associated with important negative implications for oral health.",
author = "Ardita Aliko and Andy Wolff and Colin Dawes and Doron Aframian and Gordon Proctor and J{\"o}rgen Ekstr{\"o}m and Nagamani Narayana and Alessandro Villa and Sia, {Ying Wai} and Joshi, {Revan Kumar} and Richard McGowan and {Beier Jensen}, Siri and Kerr, {A. Ross} and {Lynge Pedersen}, {Anne Marie} and Arjan Vissink",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.oooo.2014.10.027",
language = "English (US)",
volume = "120",
pages = "185--206",
journal = "Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology",
issn = "2212-4403",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - World Workshop on Oral Medicine VI

T2 - Clinical implications of medication-induced salivary gland dysfunction

AU - Aliko, Ardita

AU - Wolff, Andy

AU - Dawes, Colin

AU - Aframian, Doron

AU - Proctor, Gordon

AU - Ekström, Jörgen

AU - Narayana, Nagamani

AU - Villa, Alessandro

AU - Sia, Ying Wai

AU - Joshi, Revan Kumar

AU - McGowan, Richard

AU - Beier Jensen, Siri

AU - Kerr, A. Ross

AU - Lynge Pedersen, Anne Marie

AU - Vissink, Arjan

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective This study aimed to systematically review the available literature on the clinical implications of medication-induced salivary gland dysfunction (MISGD). Study Design The systematic review was performed using PubMed, Embase, and Web of Science (through June 2013). Studies were assessed for degree of relevance and strength of evidence, based on whether clinical implications of MISGD were the primary study outcomes, as well as on the appropriateness of study design and sample size. Results For most purported xerogenic medications, xerostomia was the most frequent adverse effect. In the majority of the 129 reviewed papers, it was not documented whether xerostomia was accompanied by decreased salivary flow. Incidence and prevalence of medication-induced xerostomia varied widely and was often associated with number and dose of medications. Xerostomia was most frequently reported to be mild-to-moderate in severity. Its onset occurred usually in the first weeks of treatment. There was selected evidence that medication-induced xerostomia occurs more frequently in women and older adults and that MISGD may be associated with other clinical implications, such as caries or oral mucosal alterations. Conclusions The systematic review showed that MISGD constitutes a significant burden in many patients and may be associated with important negative implications for oral health.

AB - Objective This study aimed to systematically review the available literature on the clinical implications of medication-induced salivary gland dysfunction (MISGD). Study Design The systematic review was performed using PubMed, Embase, and Web of Science (through June 2013). Studies were assessed for degree of relevance and strength of evidence, based on whether clinical implications of MISGD were the primary study outcomes, as well as on the appropriateness of study design and sample size. Results For most purported xerogenic medications, xerostomia was the most frequent adverse effect. In the majority of the 129 reviewed papers, it was not documented whether xerostomia was accompanied by decreased salivary flow. Incidence and prevalence of medication-induced xerostomia varied widely and was often associated with number and dose of medications. Xerostomia was most frequently reported to be mild-to-moderate in severity. Its onset occurred usually in the first weeks of treatment. There was selected evidence that medication-induced xerostomia occurs more frequently in women and older adults and that MISGD may be associated with other clinical implications, such as caries or oral mucosal alterations. Conclusions The systematic review showed that MISGD constitutes a significant burden in many patients and may be associated with important negative implications for oral health.

UR - http://www.scopus.com/inward/record.url?scp=84941982759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941982759&partnerID=8YFLogxK

U2 - 10.1016/j.oooo.2014.10.027

DO - 10.1016/j.oooo.2014.10.027

M3 - Article

C2 - 25861957

AN - SCOPUS:84941982759

VL - 120

SP - 185

EP - 206

JO - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

JF - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

SN - 2212-4403

IS - 2

ER -